MedPath

Assessment of an Investigational Frequent Replacement Silicone Hydrogel Lens

Not Applicable
Completed
Conditions
Refractive Ametropia
Interventions
Device: LID015385 soft contact lenses
Device: Comfilcon A soft contact lenses
Registration Number
NCT04085328
Lead Sponsor
Alcon Research
Brief Summary

The purpose of this clinical trial is to evaluate the safety and performance of an investigational soft contact lens compared to a commercially available soft contact lens when worn in an extended wear modality.

Detailed Description

Subjects will be expected to attend 9 office visits. The total expected duration of participation for each subject is approximately 12 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
675
Inclusion Criteria
  • Able to understand and sign an Informed Consent Form.
  • Willing to attend all scheduled study visits as required per protocol.
  • Willing and able to wear assigned study lenses as required per protocol.
  • Successful wear of spherical daily wear or extended wear frequent replacement soft contact lenses in both eyes during the past 3 months for a minimum of 5 days per week.
  • Manifest cylinder ≤ 0.75 diopter (D) in each eye.
  • Other protocol-specified inclusion criteria may apply.
Exclusion Criteria
  • Any eye infection, inflammation, or abnormality or disease (including systemic) that contraindicates contact lens wear, as determined by the Investigator.
  • Any use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the Investigator.
  • History of eye surgery, including refractive surgery.
  • Currently pregnant or breast-feeding.
  • Monovision contact lens wearers.
  • Daily disposable contact lens wearers.
  • Other protocol-specified exclusion criteria may apply.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
LID015385LID015385 soft contact lensesLID015385 soft contact lenses worn in both eyes for up to 6 nights/7 days continuously (awake and asleep). Must sleep 1 night per week without lenses. Lenses will be replaced as specified in the study protocol.
BiofinityComfilcon A soft contact lensesComfilcon A soft contact lenses worn in both eyes for up to 6 nights/7 days continuously (awake and asleep). Must sleep 1 night per week without lenses. Lenses will be replaced as specified in the study protocol.
Primary Outcome Measures
NameTimeMethod
Distance Visual Acuity (VA) With Study Lenses - Completed EyesDay 1 Dispense; Hour 24 Follow-Up; Week 1 Follow-up; Month 1 Follow-up; Month 2 Follow-up; Month 3 Follow-up; Month 6 Follow-up; Month 9 Follow-up, Month 12 Follow-up

Visual acuity (VA) was assessed for each eye individually with study lenses in place at a distance of 6 meters using a letter chart. VA was collected in Snellen and converted to logarithm minimum angle of resolution (logMAR). A logMAR value of 0 equates to 20/20 Snellen visual acuity (normal distance eyesight), with lower logMAR values indicating better visual acuity. No formal hypothesis was formulated for the primary effectiveness endpoint of distance VA; hence, no inferential testing was performed.

Distance Visual Acuity (VA) With Study Lenses - Discontinued EyesDay 1 Dispense; Hour 24 Follow-Up; Week 1 Follow-up; Month 1 Follow-up; Month 2 Follow-up; Month 3 Follow-up; Month 6 Follow-up; Month 9 Follow-up

Visual acuity (VA) was assessed for each eye individually with study lenses in place at a distance of 6 meters using a letter chart. VA was collected in Snellen and converted to logarithm minimum angle of resolution (logMAR). A logMAR value of 0 equates to 20/20 Snellen visual acuity (normal distance eyesight), with lower logMAR values indicating better visual acuity. No formal hypothesis was formulated for the primary effectiveness endpoint of distance VA; hence, no inferential testing was performed.

Proportion of Ocular Serious and Significant Non-serious Adverse Device Effects (ADEs)Up to Month 12

Calculated as the total number of eyes reporting at least one treatment-emergent, ocular, serious ADE or treatment-emergent, ocular, significant, non-serious ADE, divided by the total number of eyes enrolled and dispensed. An ADE was defined as any adverse event related to the use of the investigational medical device (LID015385) or control product (Biofinity).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (42)

Kannarr Eye Care, LLC

🇺🇸

Pittsburg, Kansas, United States

Complete Eye Care of Medina

🇺🇸

Medina, Minnesota, United States

Fischer Laser Eye Center, LLC

🇺🇸

Willmar, Minnesota, United States

Complete Family Vision Care

🇺🇸

San Diego, California, United States

Kurata Eye Care Center

🇺🇸

Los Angeles, California, United States

Westview Optometry

🇺🇸

San Diego, California, United States

ProCare Vision Centers, Inc.

🇺🇸

Granville, Ohio, United States

Winston Eye Care

🇺🇸

Fullerton, California, United States

East West Eye Institute

🇺🇸

Los Angeles, California, United States

Kindred Optics at Maitland Vision Center

🇺🇸

Maitland, Florida, United States

Alterman, Modi & Wolter

🇺🇸

Poughkeepsie, New York, United States

North Spartanburg Eye Center

🇺🇸

Boiling Springs, South Carolina, United States

Total Eye Care, PA

🇺🇸

Memphis, Tennessee, United States

Dawn M Rakich, OD

🇺🇸

San Antonio, Texas, United States

Family EyeCare Center

🇺🇸

Campbell, California, United States

Dr.Elsa Pao, O.D

🇺🇸

Oakland, California, United States

Gordon Schanzlin New Vision Institute

🇺🇸

San Diego, California, United States

Mid Florida Eye Center, PA

🇺🇸

Mount Dora, Florida, United States

OMEGA Vision Center PA, DBA Sabal Eye Care

🇺🇸

Longwood, Florida, United States

Eola Eyes

🇺🇸

Orlando, Florida, United States

Vision Health Institute

🇺🇸

Orlando, Florida, United States

Golden Vision

🇺🇸

Sarasota, Florida, United States

Advanced Eyecare Specialists

🇺🇸

West Palm Beach, Florida, United States

VisionPoint Eye Center

🇺🇸

Bloomington, Illinois, United States

Franklin Park Eye Center, PC

🇺🇸

Franklin Park, Illinois, United States

Fraser Eye Care Center

🇺🇸

Fraser, Michigan, United States

Tekwnai Vision Center, Inc

🇺🇸

Saint Louis, Missouri, United States

Dr. Schwartz Optometrist and Associates

🇺🇸

Sterling Heights, Michigan, United States

Asheville Eye Associates, PLLC

🇺🇸

Asheville, North Carolina, United States

Rochester Ophthalmological Group, PC

🇺🇸

Rochester, New York, United States

EyeCare Professionals, Inc. DBA Insight Research Clinic, LLC

🇺🇸

Powell, Ohio, United States

Midwest Vision Care

🇺🇸

Piqua, Ohio, United States

Wyomissing Optometric Center

🇺🇸

Wyomissing, Pennsylvania, United States

West Bay Eye Associates

🇺🇸

Warwick, Rhode Island, United States

Advancing Vision Research, LLC

🇺🇸

Smyrna, Tennessee, United States

Beaumont Family Eye Care

🇺🇸

Beaumont, Texas, United States

Clarke EyeCare Center

🇺🇸

Wichita Falls, Texas, United States

Primary Eyecare Group, PC

🇺🇸

Brentwood, Tennessee, United States

Vision One Eyecare

🇺🇸

Katy, Texas, United States

Optimum Vision Care

🇺🇸

Brighton, Massachusetts, United States

Visual Performance Center Research & Development

🇺🇸

Pensacola, Florida, United States

Optometry Group, PLLC

🇺🇸

Memphis, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath